17th Aug 2007 07:00
Minster Pharmaceuticals PLC17 August 2007 For immediate release 17 August 2007 MINSTER PHARMACEUTICALS PLC ("Minster" or "the Company") AIM Rule 26 Minster Pharmaceuticals plc (AIM: MPM), the drug development companyspecialising in neurological and psychiatric disorders, announces that itswebsite (www.minsterpharma.com) has been updated to comply with the requirementsof AIM Rule 26. The specific information required to be disclosed by AIM Rule 26 (companyinformation disclosure) is available on the Company's website atwww.minsterpharma.com/rule26.asp. For further information: Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623Paul Sharpe, Chief Executive OfficerRobert Aubrey, Chief Financial Officer Buchanan Communications Tel: +44 (0) 20 7466 5000Mark CourtRebecca Skye Dietrich Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200Richard PottsGerard Harper Notes for editors: About Minster Pharmaceuticals plc Minster Pharmaceuticals is a drug development company focussed on neurologicaland psychiatric disorders. Its principal pipeline assets are tonabersat, underdevelopment in the preventive treatment of migraine, and sabcomeline inschizophrenia. Worldwide rights to both compounds were acquired fromGlaxoSmithKline and the compounds benefit from comprehensive safety tolerancedata as a result of investment by GSK. Tonabersat is the most advanced compound in an exciting new class of drugscalled gap junction blockers, which have significant potential in the preventionof migraine and other major neurological conditions. Sabcomeline, a muscarinicpartial agonist, has potential in the treatment of chronic schizophrenia. Minster's near-term focus is on the development and commercialisation of itscurrent pipeline. Its medium term strategy is to leverage the anticipatedcashflows from the current pipeline by in-licensing further compounds with theultimate objective of creating a substantial and highly efficient drugdevelopment enterprise focussed on the central nervous system. Minster joined the AIM market in February 2005 and trades under the symbol MPM.For further information please visit www.minsterpharma.com . This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
MPM.L